-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Oncotelic Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and change rate from Q2 2019 to Q2 2025.
- Oncotelic Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending 30 Jun 2025 was 0 USD/shares.
- Oncotelic Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -0.02 USD/shares, a 300% decline from 2022.
- Oncotelic Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was 0.01 USD/shares.
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)